Article
The NQO1*2/*2 polymorphism is associated with poor overall survival in patients following resection of stages II and IIIa non-small cell lung cancer.
Oncology reports - 1 Jun 2011
Kolesar Jill M, Dahlberg Suzanne E, Marsh Sharon, McLeod Howard L, Johnson David H, Keller Steven M, Schiller Joan H
Abstract excerpt
NAD(P)H:quinone oxidoreductase 1 (NQO1), is a cytosolic flavoenzyme that catalyzes the two-electron reduction of quinones into hydroquinones. A polymorphism (NQO1*2) alters enzymatic activity of NQO1 resulting in diminished NQO1 activity. Malignancies with NQO1*2 may be resistant to radiation and...
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Biomarkers, Tumor
- Carcinoma, Non-Small-Cell Lung
- Cisplatin
- Combined Modality Therapy
- Etoposide
- Female
- Genotype
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms
- Male
- NAD(P)H Dehydrogenase (Quinone)
